Journal of cancer research and therapeutics最新文献

{"title":"Complete response in a patient with metastatic metaplastic breast cancer treated with immune checkpoint inhibitor and chemotherapy: A case report and a review of the literature.","authors":"Jinghua Chen, Jie Liu, Yixuan Li, Chao Liu, Xiaoyue Zhang, Baishan Zheng, Linxin Si, Mingzhu Zhang, Xi Zhang, Shutao Xu, Weiwei Nie, Jun Wang","doi":"10.4103/jcrt.jcrt_285_25","DOIUrl":"10.4103/jcrt.jcrt_285_25","url":null,"abstract":"<p><strong>Abstract: </strong>Metaplastic breast cancer (MpBC) is a rare subtype of breast cancer characterized by poor prognosis and lack of treatment guidance. It is notably resistant to conventional chemotherapy. Currently, immunotherapy is becoming a promising option for multiple tumor types, including triple-negative breast cancer. This report presents a case of triple-negative MpBC that achieved a complete response with a combination of chemotherapy and immune checkpoint inhibitors. We examined the tumor's imaging and histological features, along with the treatment regimen and efficacy. Notably, no major toxicities related to immunotherapy were observed. To our knowledge, this is the first case report demonstrating the effectiveness of lambrolizumab in combination with the GP chemotherapy regimen for treating triple-negative breast cancer in general and specifically metastatic MpBC.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 4","pages":"955-959"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a risk signature based on disulidptosis-related ferroptosis genes in ovarian cancer.","authors":"Yaxin Sun, Lidong Liu, Fatao Guo, Zhenwei Jin, Yueyuan Miao, Yingchun Ma","doi":"10.4103/jcrt.jcrt_28_25","DOIUrl":"10.4103/jcrt.jcrt_28_25","url":null,"abstract":"<p><strong>Background: </strong>Disulfidptosis and ferroptosis, newly identified forms of cell death, have attracted widespread attention; however, their relationship with ovarian cancer (OC) prognosis remains unclear.</p><p><strong>Methods: </strong>We constructed a multivariate Cox risk signature comprising three key genes: CREB3, PIEZO1, and SLC7A11. Patients were stratified into high- and low-risk groups based on the optimal cutoff value of the risk score. Subsequently, survival analysis was conducted in the training group (TCGA-OV) and external databases (GSE26712 and GSE63885), with the predictive efficiency of the risk signature evaluated through ROC curves.</p><p><strong>Results: </strong>Prognosis was significantly better for patients in the low-risk group than in the high-risk group. Compared to single clinical features such as age and stage, the risk score had the highest diagnostic value for prognostic evaluation. Based on gene function and pathway analyses, differential genes were found to be related to oxidative stress. Immune infiltration analysis indicated that risk scores were associated with immunosuppressive cells such as M2 macrophages. Finally, the protein expression levels of the key gene CREB3 in OC tissues were evaluated in vitro.</p><p><strong>Conclusion: </strong>This study might provide significant value for exploring the relationship between disulfidptosis-related ferroptosis genes and OC, and its results may provide insights on new therapeutic targets for OC.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 4","pages":"851-863"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Side effects of boron neutron capture therapy.","authors":"Yushu Zhang, Yufeng Cheng","doi":"10.4103/jcrt.jcrt_2743_23","DOIUrl":"10.4103/jcrt.jcrt_2743_23","url":null,"abstract":"<p><strong>Abstract: </strong>Boron neutron capture therapy (BNCT) is an innovative cancer treatment modality that selectively eliminates tumor cells while sparing normal tissues. Clinical studies have explored its application across various malignancies, including malignant gliomas, meningiomas, pediatric tumors, head and neck cancers, and melanomas. However, despite its therapeutic potential, BNCT is associated with various adverse effects that differ depending on the tumor type, neutron source, boron delivery agent, and treatment protocol. These adverse reactions pose significant challenges to the broader clinical implementation of this approach. This review systematically examines the adverse effects of BNCT observed in clinical studies, focusing on their underlying mechanisms, contributing factors, and tumor-specific variations. Additionally, it highlights current strategies for managing and preventing these effects and emphasizes the need for further research to address unresolved challenges. This article aims to provide comprehensive insights into the adverse effects of BNCT, supporting the development of safer and more effective treatment protocols and ultimately advancing their role in precision oncology.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 4","pages":"777-786"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective study of the characteristics of early gastric cancer with surrounding map-like redness after successful Helicobacter pylori eradication.","authors":"Yubei Li, Yali Wei, Yanan Yu, Xiaoyan Yin","doi":"10.4103/jcrt.jcrt_2039_24","DOIUrl":"10.4103/jcrt.jcrt_2039_24","url":null,"abstract":"<p><strong>Background: </strong>Map-like redness (MLR) is a high-risk membrane factor for early gastric cancer (EGC) after the successful eradication of Helicobacter pylori (Hp). This study aimed to analyze the clinical, endoscopic, and pathological characteristics of EGC with surrounding MLR after successful Hp eradication and evaluate the effect of endoscopic submucosal dissection (ESD) resection.</p><p><strong>Methods: </strong>This retrospective study comprised 23 patients with EGC and surrounding MLR after Hp eradication (MLR group) and 135 patients with EGC without a surrounding MLR (non-MLR; NMLR group). The clinical, pathological, and endoscopic characteristics were compared, and the effect of ESD resection was evaluated.</p><p><strong>Results: </strong>A total of 158 patients were enrolled (age range: 41-77 years). The MLR group had a higher proportion of males (P = 0.020) and more severe atrophy (P = 0.003) and intestinal metaplasia (P = 0.007) than the NMLR group. The endoscopic features of the MLR group included localization in the middle part of the stomach (P < 0.001), a red color (P = 0.002), a larger size (P = 0.015), a greater proportion of type IIb tumors (P < 0.001), and unclear lesion borders (P < 0.001) compared to the NMLR group. Differentiated adenocarcinoma was the main histological type in the MLR group (P = 0.023). No significant difference in curative resection rates was observed between the groups.</p><p><strong>Conclusion: </strong>The MLR group presented with a greater risk of pathological upgrading after ESD. The findings indicate that ESD is most effective for treating EGC with adjacent MLR after Hp eradication.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 4","pages":"948-954"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare case of primary retroperitoneal transitional cell carcinoma achieving pathological complete response with combined modality treatment.","authors":"Mahesh B Gejji, Narendra Hulikal, Nagesh K Singaram, Maduri Alekhya","doi":"10.4103/jcrt.jcrt_1759_24","DOIUrl":"10.4103/jcrt.jcrt_1759_24","url":null,"abstract":"<p><strong>Abstract: </strong>Primary retroperitoneal transitional cell carcinomas (TCCs) are very rare tumors arising from the urogenital ridge remnants. Till date only eight cases have been reported. Recently, we treated a patient who presented with an advanced, large tumor with major vascular infiltration with chemotherapy and radiotherapy before surgery. Though preoperative imaging did not show much response, the tumor could be resected completely along with the left kidney and part of the abdominal wall. Final histopathological examination revealed no viable tumor in the entire specimen. This case report details the clinical and management aspects of such a rare tumor with a review of the previously reported cases.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"1091-1094"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors and treatment of ısolated recurrence in vulvar cancer confined to the vulva or perineum.","authors":"Kemal Güngördük, Fuat Demirkiran, Ghanim Khatib, Murat Öz, Varol Gülseren, Yagmur Minareci, Muzaffer Sanci, Hanifi Şahin, Özgür Tosun, Salih Taskin, Levent Akman, Bülent Özçelik, Selen Dogan, Yakup Yalçin, İbrahim Yalcın, Sükrü Çebi, Hamdullah Sözen, Dogan Vatansever, Nasuh U Dogan, Abdullah S Açikgöz, Kemal Özerkan, Cosan Terek, Koray Aslan, Tufan Öge, Çagatay Taskıran, Firat Ortaç, Mehmet A Vardar, Ali Ayhan, Macit Arvas","doi":"10.4103/jcrt.jcrt_1698_24","DOIUrl":"10.4103/jcrt.jcrt_1698_24","url":null,"abstract":"<p><strong>Aim: </strong>This study evaluated predictors and treatment of isolated vulvar recurrence (IVR) in patients with stage I-II tumors locally confined to the vulva.</p><p><strong>Methods: </strong>We retrospectively collected data from patients with stage I-II vulvar squamous cell carcinoma (VSCC) who underwent surgery for vulvar cancer between 2005 and 2021. The IVR group comprised patients with stage I-II tumors at the time of initial diagnosis who developed recurrence confined to the vulvar region after initial treatment.</p><p><strong>Results: </strong>This study included 416 patients with early-stage (stage I-II) VSCC. IVR was developed in 67 (16.1%) patients; the remaining 349 patients were included in the control group. Independent predictors of IVR were depth of invasion, perineural invasion, and positive surgical margins. Among patients with tumors confined to the vulva at the time of initial diagnosis, the 5-year overall survival rates were 59.0% and 87.0% in the IVR and control groups, respectively (P < 0.001). In the IVR group, the cumulative rates of local relapse were 38.8% in the first year, 58.2% in the second year, and 74.6% in the third year.</p><p><strong>Conclusion: </strong>Independent predictors of IVR in early-stage VSCC were depth of invasion, perineural invasion, and positive surgical margins. Approximately two-thirds of local recurrences occurred in the first 3 years after treatment.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"1059-1063"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scrotal metastasis of colorectal carcinoma with unusual presentation and late recurrences: A study from a tertiary care oncology center in India.","authors":"Disha Bilala, Subhash Yadav, Suman Kumar Ankathi, Rajiv Kumar, Gauri Deshpande, Munita Bal, Kedar Deodhar, Santosh Menon, Mukta Ramadwar","doi":"10.4103/jcrt.jcrt_446_24","DOIUrl":"10.4103/jcrt.jcrt_446_24","url":null,"abstract":"<p><strong>Background: </strong>Colorectal carcinoma (CRC) is a common malignancy, frequently metastasizing to the liver, lungs, and regional lymph nodes. However, metastasis to the scrotum is exceedingly rare, with few cases reported in the literature. In this study, we present a series of five cases of CRC metastasizing to the scrotum, emphasizing their unusual clinical presentation and late recurrences.</p><p><strong>Methods: </strong>We did a retrospective review of 7 years from 2015 to 2022 for cases of scrotal metastasis in cases of CRC.</p><p><strong>Results: </strong>The mean age in our study was 38 years (22-61 years) and the median time interval between the primary diagnosis and scrotal metastasis was 31.6 months (0-104 months). The cases include scrotal swelling initially misdiagnosed as a hydrocele (case 1), nonhealing cutaneous ulcers (cases 3 and 5), a scrotal skin papilloma (case 4), and a cutaneous nodule (case 2).</p><p><strong>Conclusion: </strong>This series of five cases highlights the rarity and diagnostic challenges associated with CRC metastasizing to the scrotum. The extended latency between primary tumor diagnosis and scrotal metastasis, coupled with atypical clinical presentations, underscores the importance of maintaining a high index of suspicion. Clinicians should be vigilant, especially when evaluating patients with a history of CRC, to promptly identify such uncommon metastatic sites.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"1026-1031"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic profiling of head and neck adenoid cystic carcinoma: A systematic review and meta-analysis.","authors":"Madhur Sharma, Anjali Narwal, Mala Kamboj, Anju Devi, Adarsh Kumar, Gopikrishnan Vijayakumar","doi":"10.4103/jcrt.JCRT_908_25","DOIUrl":"10.4103/jcrt.JCRT_908_25","url":null,"abstract":"<p><strong>Abstract: </strong>Head and neck adenoid cystic carcinoma (ACC) is a common malignancy often associated with an aggressive clinical course and a wide array of gene mutations. This systematic review aimed to determine the prevalence of these mutations and their association with prognosis and recurrence in ACC. A search of the scientific literature was carried out from inception till 31 July 2024 in the electronic databases - PubMed, EMBASE, Scopus, Web of Science, Ovid/MEDLINE, and Science direct following specific eligibility criteria. The methodological quality of the included studies was assessed using the Newcastle-Ottawa tool. 31 studies were included, and numerous genes like MYB, NOTCH, TP53, PIK3CA, ARID1A, KDM6A, RAS, SPEN, and many more were identified and were related to poor prognosis. Identification of different genes using wide NGS panels and combination of molecular techniques becomes necessary as multiple genes might be involved in ACC pathogenesis and subsequent targeted therapies can be designed.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"971-981"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypofractionated radiotherapy in carcinoma breast - A 5-year single institution experience.","authors":"Pardeep Garg, Navik Goyal, Sheenu Priya, Romi Grover, Simrandeep Singh","doi":"10.4103/jcrt.jcrt_282_24","DOIUrl":"10.4103/jcrt.jcrt_282_24","url":null,"abstract":"<p><strong>Background: </strong>Hypofractionated Radiotherapy has replaced Conventional Radiotherapy in Carcinoma Breast. This study aimed to assess locoregional failure, disease-free survival, and overall survival in patients treated over 5 years in our institution.</p><p><strong>Materials and methods: </strong>A total of 453 patients with carcinoma of the breast eligible for whole breast radiotherapy were assessed from January 2018 to December 2023. Two-dimensional Radiotherapy was given via Telecobalt or LINAC. Demographic, disease, and treatment-related data were analyzed.</p><p><strong>Results: </strong>Median follow-up was 2.75 years (Range 0.3-5.2 years). Breast-conserving surgery and modified radical mastectomy were done in 21.81% and 78.18% of patients respectively. Neoadjuvant chemotherapy was given in 55.2% of cases. Pathologically, 54.2% of patients had Stage IIB-IIIB and 45.7% had I-IIA.70.84% were given 42 Gy/15 # and the rest of them were given either 41.6 Gy/16 # or 40 Gy/15 #. Percentages of acute skin toxicities Grade I, II, and chronic were observed in 23.11%, 3.97%, and 5.07%, respectively. There were a total of 16 locoregional recurrences and 27 cases of distant metastasis in 5 years. Overall survival and disease-free survival after 5 years were 94.2% and 90.5%, respectively.</p><p><strong>Conclusion: </strong>Hypofractionated radiotherapy is a safe and efficacious choice for radical treatment of carcinoma breast patients post-surgery. It provides superlative results in concern to disease-free survival and overall survival with minimal acute and chronic toxicities.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"995-999"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of response to total neoadjuvant therapy in carcinoma rectum: A real-world prospective observational study from eastern India.","authors":"Priyanka Mukherjee, Sandip K Barik, Saroj K D Majumdar, Deepak K Das, Mathan K Ramasubbu, Sk S Ahmed, Dillip K Muduly, Prakash K Sasmal, Tushar S Mishra, Bramhadatta Pattnaik, Tanmay Dutta, Sunita Gupta, Sovan S Dhar, Ashutosh Pattanaik, Bikash R Mahapatra, Avinash Badajena, Minakshi Mishra, Satyabrata Kanungo, K M Nehla Haroon, U Poornima Devi, Anupam Muraleedharan, Ankur Mahajan, Shaha S Abdulla, Arnab Sarkar, Dillip K Parida","doi":"10.4103/jcrt.jcrt_742_25","DOIUrl":"10.4103/jcrt.jcrt_742_25","url":null,"abstract":"<p><strong>Background: </strong>Preoperative chemoradiotherapy and subsequent surgery is the standard of care for locally advanced rectal cancer. This has resulted in good local control, but without a significant survival benefit. Multiple randomised trials have utilised total neoadjuvant therapy (TNT) to improve survival outcomes. However, clinical experience in India is limited.</p><p><strong>Methods: </strong>Patients with cT3/4 or N + rectal adenocarcinoma with ECOG 0-1 were included. Treatment course comprised Short-course radiotherapy (25 Gy in 5 fractions over 1 week), followed by 6 cycles of chemotherapy (Inj. oxaliplatin 130 mg/m2 on D1 and Tab capecitabine 1000 mg/m2 BID from D1-14, q21 days). Following the completion of neoadjuvant treatment, patients were assessed for surgery. Surgery involved Total Mesorectal Excision.</p><p><strong>Results: </strong>32 patients were enrolled. Males comprised 66% of the population, and the median age was 42 years. 75% of patients had distal rectal tumours. 18.8% were signet ring cell carcinoma (SRC). 43.8% of patients had mesorectal fascia involvement and lateral lymph nodes (LLN) were present in 28% patients. All patients completed the full course of TNT. 84.4% patients underwent definitive surgery. Pathological complete response was reported in 37% patients, with R0 resection in 96%. Sphincter preservation could be achieved in 29.2% of distal tumours. The incidence of acute grade 3 or higher adverse events was 40.6%, the most common being diarrhoea (15.6%), followed by anaemia (9.4%). Post-operative complications were seen in 22.2% of patients, the most frequent being delayed wound healing. The incidence of Clavien-Dindo grade IV complications was 3.7%. At a median follow-up of 2 years, OS and PFS were 75% and 59.4%, respectively. Absence of LLN and non-SRC histology was associated with significantly higher PFS and OS.</p><p><strong>Conclusion: </strong>The TNT protocol we followed was well tolerated in our patient population. Excellent tumour and nodal regression rates were seen. It can be considered a viable alternative to preoperative conventional chemoradiation, particularly in a resource-limited setting. However, this treatment strategy was not optimal for patients with high-risk features such as the presence of LLNs and SRC histology.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 5","pages":"1038-1045"},"PeriodicalIF":1.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}